Aberdeen Group
ZNTL icon

Aberdeen Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Aberdeen Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40,156
Closed -$608K – 975
2023
Q4 		$608K Buy
+40,156
New +$586K ﹤0.01% 868

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Aberdeen Group's ZNTL Position: Q1 2024 in Review

Aberdeen Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2024, closing a stake of 40,156 shares — an estimated $608K sold.

Aberdeen Group first reported a position in ZNTL in Q4 2023 and held it in 1 quarter. The position peaked at $608K in Q4 2023. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

  • Aberdeen Group reported no remaining Zentalis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Aberdeen Group sold 40,156 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $608K.
  • Aberdeen Group first reported a position in Zentalis Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Aberdeen Group's Zentalis Pharmaceuticals position peaked at $608K in Q4 2023.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Aberdeen Group's 13F filing for Q1 2024, filed 9 May 2024.